Mass Spectrometry Instrumentation Patents: Top Companies & Trends 2026
- Filings have declined since 2019. The peak year was 2019 at 907 records, and by the 2022 midpoint annual filings were already back to 674 — a flat-to-declining trend, not a growing one.
- Claim activity concentrates in two IPC subclasses. H01J (electron & discharge tubes) and G01N (material analysis & testing) together account for the large majority of the 28,845 published records, with B01D, C12Q and bioinformatics-adjacent classes trailing far behind.
- Recent-year momentum is negative across the named assignees. Every tracked assignee in the recent-year momentum data shows a year-over-year decline, several down 90%+ or to zero filings in the latest year.
Filing growth compares 2021 (652 records) with 2024 (331) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 28,845 records in scope (CR5), not by the ranked leaders only.
What the mass spectrometry instrumentation patent record shows
Mass spectrometry instrumentation patents cluster around ion source design, ion optics alignment, vacuum system architecture and quantitation methods — the search construction underlying this dataset combines those claim terms with the core IPC classes for electron/discharge tubes and material analysis. Across 28,845 patent families published between 2015 and the 2026 cut-off, the technology sits mostly inside two adjacent classification buckets rather than spread evenly across the field. Publication lags filing by roughly 18 months, so the 2026 count in any trend chart is necessarily incomplete and should not be read as a real drop-off on its own.
The receiving-office split shows the United States as the dominant filing venue, with Europe, the WIPO PCT route, the United Kingdom, Canada and Australia following in that order. That pattern is consistent with an instrumentation field where a small number of established analytical-instrument makers file broadly but a long tail of academic and diagnostic entrants files narrowly, often through PCT before deciding where to enter national phase.
Filing trend and technology composition
Annual filing counts and the IPC subclass split are the two clearest signals in this dataset: one shows momentum, the other shows where claim density has actually built up.
A peak in 2019, then a decline through the mid-2020s
Filings rose to 907 in 2019, the peak year in the dataset, then eased back toward 674 by the 2022 midpoint. Combined with the 2017 count of 613, the shape is a rise-and-fall rather than sustained growth — treat the 2025-2026 tail as understated given publication lag, but the mid-decade retreat from the 2019 peak is a real signal.
H01J and G01N dominate; everything else is a minor branch
H01J (electron & discharge tubes, 17,925 records) and G01N (material analysis & testing, 9,094 records) together dwarf the remaining classes. B01D separation processes, C12Q enzyme/DNA testing, G06F data processing, C07K peptides, C12N microorganisms and G16B bioinformatics each register in the low hundreds — these are the adjacent branches where instrumentation claims meet biology and software, and where claim density is thin.
Shares are the percentage of the 28,845 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Mass Spectrometry Instrumentation with Eureka
This page is one run against one query. Ask Eureka your own question about mass spectrometry instrumentation and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited prior art and a representative claim
US7064318B2 — Methods and apparatus for aligning ion optics in a mass spectrometer
The patent, assigned to Thermo Finnigan LLC and issued in 2006, covers computer-implemented methods and apparatus for calibrating an ion source by establishing a coordinate relationship between a sample plate and a sample control system, then using that relationship to align a target region of the plate with the ion optics for mass spectrometric analysis.The claims center on fiducial-based alignment rather than on the ion optics geometry itself, which narrows what the patent actually forecloses for others.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5719060A | Method and apparatus for desorption and ionization of analytes | 756 |
| 2 | US6043031A | DNA diagnostics based on mass spectrometry | 684 |
| 3 | US5313061A | Miniaturized mass spectrometer system | 658 |
| 4 | US5420425A | Ion trap mass spectrometer system and method | 639 |
| 5 | US6204500B1 | Mass spectrometry from surfaces | 600 |
| 6 | US5847386A | Spectrometer with axial field | 597 |
| 7 | US6107623A | Methods and apparatus for tandem mass spectrometry | 596 |
| 8 | US6124137A | Surface-enhanced neat desorption and detection of analytes | 575 |
| 9 | US6268144B1 | DNA diagnostics based on mass spectrometry | 569 |
| 10 | US6177668B1 | Axial ejection in a multipole mass spectrometer | 494 |
Citation counts inside a searched corpus favour older, foundational filings — read these as markers of influence on later drafting, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Reading the filing and citation data
Three patterns stand out once the raw counts are set against each other: where claim density sits, how citation age skews the influence picture, and what the receiving-office split implies about filing strategy.
Electron & discharge tube claims dominate
H01J alone accounts for well over half of all published records in this dataset, meaning ion source and detector hardware claims are the most heavily occupied part of the field. G01N material-analysis claims form the second-largest bloc, but the gap to every other class is wide.
The most-cited art predates the 2015 filing window
The top-cited records — covering desorption/ionization methods, DNA diagnostics by mass spectrometry, and early ion trap and miniaturized systems — were granted well before the 2015-2026 window this dataset tracks. Their citation counts reflect decades of accumulated influence, not recent relevance.
US-first filing with a PCT safety net
The United States receives more than triple the filings of the next-largest single office (EPO). The PCT route sits third, ahead of direct UK filing, suggesting many applicants use PCT to defer national-phase decisions rather than filing directly into multiple offices upfront.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to mass spectrometry instrumentation, with the prior art for and against each one.
Assignee landscape and where momentum has gone
The recent-year momentum figures point in one direction across every tracked assignee: filing activity in this specific search construction has slowed sharply, even among the instrument makers with the deepest legacy portfolios.
Established instrument makers have gone quiet
Assignees with long-standing mass spectrometry portfolios show zero filings in the latest tracked year against a prior-year base, a -100% year-over-year reading. Combined with double-digit percentage declines at several diagnostics-focused assignees, the pattern is broad rather than isolated to one company.
A small number of collaboration pairs stand out
Ten co-assignee pairs are documented in this dataset, with the strongest pairing spanning roughly 93 shared families and two further pairs in the 50-72 range. These are the clearest evidence of sustained joint filing relationships rather than one-off co-applications.
Diagnostics-side assignees are still filing, just less
Unlike the instrument makers at zero, diagnostics-focused assignees retain a small but non-zero latest-year filing count, still down sharply year over year. This suggests the diagnostics application layer is contracting on the same trajectory as the core instrumentation side, just from a lower base.
| Assignee | Recent year | YoY |
|---|---|---|
| Quest Diagnostics Investments LLC | 5 | -62% |
| DH Technologies Development Pte. Ltd. | 1 | -94% |
| Thermo Fisher Scientific (Bremen) GmbH | 1 | -94% |
| Agilent Technologies, Inc. | 1 | -67% |
| Micromass UK Limited | 0 | -100% |
| Shimadzu Corporation | 0 | -100% |
| Thermo Finnigan LLC | 0 | -100% |
| BRUKER DALTONIK GMBH | 0 | — |
Where to take this analysis
The dataset points to a mature, densely claimed core and a contracting filing rate — the open questions are about specific claim boundaries and adjacent white space, not about whether the field is active.
Map the ion optics and vacuum system claim boundaries
With H01J carrying the largest share of records, a targeted claim chart on ion optics alignment and vacuum system architecture will show exactly how much room remains around the most-cited foundational patents.
Run a claim comparison in EurekaCheck freedom to operate in the under-claimed branches
Bioinformatics, enzyme/DNA quantitation and peptide-specific claims carry a fraction of the H01J/G01N filing volume — that gap is worth verifying before assuming it is open.
Search white space in EurekaTrack whether the post-2019 decline continues
Filings fell from a 2019 peak of 907 toward 674 by 2022, and every tracked assignee shows negative recent-year momentum — worth revisiting once the 2025-2026 publication lag clears.
Set up a filing trend alert in EurekaCommon questions about mass spectrometry instrumentation patents
Based on citation counts within this dataset, the most-cited records include US5719060A on desorption and ionization of analytes, US6043031A on DNA diagnostics by mass spectrometry, and US5313061A on a miniaturized mass spectrometer system, each cited over 600 times. These are older, foundational filings rather than recent ones, so high citation counts reflect decades of influence on later drafting rather than current commercial activity. Anyone drafting new ion source or detector claims should expect to cite or design around this cluster.
No — filings peaked at 907 in 2019 and had fallen back to 674 by the 2022 midpoint, and recent-year momentum data shows every tracked assignee down year over year, several to zero. The 2025-2026 figures are understated because publication typically lags filing by about 18 months, but the mid-decade retreat from the 2019 peak predates that lag effect. Overall the trend reads as flat-to-declining rather than growing.
H01J, covering electron and discharge tubes, accounts for 17,925 of the 28,845 records in this dataset — by far the largest single class. G01N, material analysis and testing, is second at 9,094 records. Everything else, including separation processes, enzyme/DNA testing, data processing, peptide chemistry and bioinformatics, trails well behind, each in the low hundreds, marking those as the thinner, more open branches of the field.
The receiving-office data shows the United States as the dominant venue at 8,820 filings, more than double the next office, the EPO at 4,007. The WIPO PCT route ranks third at 2,462, ahead of direct UK, Canadian and Australian filing, indicating many applicants use PCT to keep national-phase options open rather than committing to multiple offices immediately. Filing strategy should follow where the applicant expects to sell or license the instrument, but the US-first pattern in this data is worth matching unless there's a specific reason not to.
US7064318B2, assigned to Thermo Finnigan LLC, covers a specific method of calibrating an ion source by aligning a sample plate's coordinate system with the ion optics using fiducial markers — it does not claim ion optics geometry or ion source hardware broadly. That narrows its practical blocking effect to fiducial-based alignment calibration methods rather than to ion optics design generally. Designers working on alternative alignment approaches, such as non-fiducial or sensor-based calibration, would sit outside this specific claim scope, though a full freedom-to-operate check against the broader H01J class is still advisable given how dense that class is.
Research Mass Spectrometry Instrumentation in depth with Eureka
Go past this page: query the whole mass spectrometry instrumentation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.